Advertisement

Volume 132, Issue 21

 

 

November 22, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Subset of MDS characterized by disrupted TGF-β signaling and aberrant splicing signature. See the article by Muench et al.

SKI controls MDS-associated chronic TGF-β signaling, aberrant splicing, and stem cell fitness
The investigators identify a subset of myelodysplastic syndrome (MDS) characterized by disruption of the transforming growth factor beta (TGF-β) signaling pathway and an abnormal splicing signature.


Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions
This review by Vazquez offers a comprehensive reference regarding clinically relevant drug-drug interactions involving oral anticoagulants.


Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib
The investigators report that in patients with chronic lymphocytic leukemia (CLL), the functionally compromised γδ T cells can recover their function after in vitro activation/expansion and/or ibrutinib treatment.


Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model
The investigators demonstrate that erythroid knockout of transferrin receptor 2 improves erythropoiesis in β-thalassemic mice, and they cast light on the underlying mechanism.


Anticoagulating patients with high-risk acquired thrombophilias
Skeith presents a timely review on the anticoagulation management of paroxysmal nocturnal hemoglobinuria and other high-risk acquired thrombophilias, with a focus on the use of oral anticoagulants.


A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
This paper reports on a pilot study of stepping down the dose of ibrutinib in chronic lymphocytic leukemia over the initial three cycles of treatment, demonstrating that its relevant cellular biologic effects are maintained at lower dose levels.


Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis
Postthrombotic syndrome (PTS) is a significant, disabling complication seen in up to 50% of patients with venous thromboembolism (VTE). This study provides data showing that early compression therapy post VTE is effective in decreasing the incidence of PTS, reducing residual vein obstruction on follow-up ultrasound.


IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas
The study by Wagener et al provides a detailed, state-of-the-art genetic analysis of pre-Burkitt lymphoma (BL), ie, lymphoid tumors that carry the MYC translocation typical of BL but display a more immature B-cell phenotype.


Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
This article presents the first study on the toxicity, response rates, and outcomes of an immunomodulatory imide drug (IMID) in patients with relapsed primary central nervous system (CNS) lymphoma.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.